-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rimtoregtide in Cytokine Release Syndrome (Cytokine Storm)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Rimtoregtide in Cytokine Release Syndrome (Cytokine Storm) Drug Details:Rimtoregtide is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GM-6 in Acute Ischemic Stroke
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GM-6 in Acute Ischemic Stroke Drug Details:GM-6 is under development for the treatment of amyotrophic lateral...
-
Product Insights
![]()
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Sclerosis Pipeline Drugs Development Market Report Overview Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech. The...
-
Product Insights
![]()
Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Insulin-like growth factor 2 (IGF-2) is a protein hormone. IGF-2 is influenced by placental lactogen and plays a role in fetal development. It undergoes glucose-mediated co-secretion with insulin and acts as a physiological amplifier of glucose-mediated insulin secretion. The Insulin-like growth factor 2 pipeline drugs market research report provides comprehensive information on the therapeutics under development for insulin-like growth factor 2, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule...
-
Product Insights
![]()
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin. It plays a role in synapse maturation. It acts as a ligand for IGF1R. The Insulin Like Growth Factor I pipeline drugs market research report provides comprehensive information on the therapeutics under development for Fibroblast Growth Factor 2, complete with analysis by stage of development,...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – GM-603
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry GM-603 Drug Details GM-603 is under development for treatment of spinal cord injury. GM603...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – GM-605
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry GM-605 Drug Details GM-605 is under development for the treatment of Alzheimer's disease. GM605...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – GM-607
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry GM-607 Drug Details GM-607 is under development for the treatment of multiple sclerosis. It...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – GM-6
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry GM-6 Drug Details GM-6 is under development for the treatment of amyotrophic lateral sclerosis,...
-
Product Insights
![]()
Spinal Cord Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida, or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head, or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet,...
-
Product Insights
![]()
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Product Insights
![]()
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
![]()
Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Stroke can occur with symptoms including sudden numbness in their face or limbs, particularly down one side of their body. The sufferer may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance. The Stroke pipeline drugs market research report outlays comprehensive information on the Stroke targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA)...
-
Product Insights
![]()
Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2. It promotes activation of CASP3, and thereby apoptosis. It undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis under stress conditions. The Apoptosis regulator BAX - Drugs in Development research report provides a comprehensive overview on the therapeutics under development...
-
Product Insights
![]()
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. The Alzheimer’s Disease Drugs in Development market research report provides an overview of the Alzheimer's Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug...
-
Product Insights
![]()
Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Amyotrophic Lateral Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
![]()
Ischemic Cerebral Stroke Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Ischemic Cerebral Stroke Global Clinical Trials Review, H2, 2016" provides an overview of Ischemic Cerebral Stroke clinical trials scenario. This report provides top line data relating to the clinical trials on Ischemic Cerebral Stroke. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
![]()
Ischemic Cerebral Stroke Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Ischemic Cerebral Stroke Global Clinical Trials Review, H2, 2017" provides an overview of Ischemic Cerebral Stroke clinical trials scenario. This report provides top line data relating to the clinical trials on Ischemic Cerebral Stroke. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
![]()
Parkinson’s Disease Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Parkinson's Disease Global Clinical Trials Review, H1, 2018" provides an overview of Parkinson's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Parkinson's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.